Apogem Capital’s Prothena Corp PRTA Stock Holding History

Apogem Capital’s Portfolio PRTA Stock Details PRTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3,800	Closed	-$230K	–	96
2022 Q3	$230K	Buy	+3,800	New	+$120K	0.23%	112
2022 Q1	–	Sell	-3,900	Closed	-$193K	–	190
2021 Q4	$193K	Buy	+3,900	New	+$216K	0.13%	161
2021 Q1	–	Sell	-10,800	Closed	-$130K	–	202
2020 Q4	$130K	Buy	+10,800	New	+$128K	0.09%	155

Other funds holding PRTA

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Apogem Capital's PRTA Position: Q4 2022 in Review

Apogem Capital sold out of Prothena Corp (PRTA) in Q4 2022, closing a stake of 22,566 shares — an estimated $1.37M sold.

Apogem Capital first reported a position in PRTA in Q4 2020 and held it in 8 quarters. The position peaked at $1.77M in Q3 2021. 201 funds tracked by Wall St. Rank hold PRTA as of Q4 2022.

Apogem Capital reported no remaining Prothena Corp position as of Q4 2022 after selling out during the quarter.
Apogem Capital sold 22,566 Prothena Corp shares in Q4 2022, an estimated $1.37M.
Apogem Capital first reported a position in Prothena Corp in Q4 2020 and held it in 8 quarters.
Apogem Capital's Prothena Corp position peaked at $1.77M in Q3 2021.
201 funds tracked by Wall St. Rank held Prothena Corp as of Q4 2022.

Based on Apogem Capital's 13F filing for Q4 2022, filed 13 Feb 2023.